Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Oracle Faces Scrutiny as Analyst Questions Cloud Business Model

Robert Sasse by Robert Sasse
October 1, 2025
in AI & Quantum Computing, Analysis, Tech & Software
0
Oracle Stock
0
SHARES
91
VIEWS
Share on FacebookShare on Twitter

Oracle finds itself at a critical juncture as conflicting narratives emerge about its true position in the cloud computing sector. While the technology giant continues to announce massive AI commitments and record cloud contract growth, a fundamental question is being raised by financial analysts: Is Oracle genuinely a cloud provider, or merely an expensive financing partner with inflated valuations?

The controversy gained significant traction in late September when investment bank Rothschild & Co’s research arm, Redburn, issued a stark “Sell” rating for Oracle shares. The firm set a price target of just $175, representing a nearly 40 percent discount to the stock’s current trading levels. This bearish assessment directly challenges the prevailing market optimism surrounding Oracle’s cloud ambitions.

Questioning the Core Business Model

At the heart of the skepticism lies Rothschild’s characterization of Oracle’s approach to large single-tenant deployments. The analysis suggests the company operates “more like a financier than a cloud provider,” with an economic model that “differs significantly from the approach investors typically value.” This fundamental challenge to Oracle’s cloud identity comes during what should be a triumphant period for the company.

Just as these doubts emerged, Oracle had revealed extraordinary growth in its remaining performance obligations, which surged 359 percent to $455 billion. This massive increase was primarily fueled by multibillion-dollar cloud agreements, including a reported $300 billion arrangement with OpenAI. Following this announcement, Oracle’s stock had climbed more than 30 percent, reflecting strong market enthusiasm.

Should investors sell immediately? Or is it worth buying Oracle?

The $60 Billion Guidance Under Microscope

Market experts are expressing particular concern about Oracle’s five-year cloud revenue guidance of approximately $60 billion. According to skeptical analysts, these ambitious targets appear fully priced into the current stock valuation and represent a “high-risk dream scenario that will likely fail to materialize.” The timing of this scrutiny is notable, given Oracle’s recent bond issuance of $18 billion in late September—one of the largest corporate debt offerings this year—to fund its aggressive AI infrastructure expansion.

The company’s internal projections outline dramatic growth targets for Oracle Cloud Infrastructure: reaching $18 billion by 2026 (a 77 percent increase), followed by progressively ambitious targets of $32 billion, $73 billion, $114 billion, and ultimately $144 billion in subsequent years. These very projections now face intense examination from financial researchers.

Balancing AI Enthusiasm with Financial Reality

Oracle currently navigates the complex territory between artificial intelligence euphoria and economic fundamentals. The company receives praise for its involvement with TikTok U.S. operations and partnerships with AI pioneers, yet warning voices about potential overvaluation are growing louder.

With a market capitalization exceeding $800 billion, Oracle now ranks among the ten most valuable U.S. companies. Its shares have advanced approximately 70 percent since the beginning of the year, though the stock has experienced volatility between $280 and $285 since reaching its September peak. This price fluctuation reflects the ongoing tension between Oracle’s promising AI positioning and emerging questions about its underlying business economics.

Ad

Oracle Stock: Buy or Sell?! New Oracle Analysis from February 8 delivers the answer:

The latest Oracle figures speak for themselves: Urgent action needed for Oracle investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Oracle: Buy or sell? Read more here...

Tags: Oracle
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Next Post
MSCI World ETF Stock

The AI Investment Wave: How Global Equity ETFs Are Capitalizing on Technological Transformation

QuantumScape Stock

QuantumScape Shares Surge on Key Manufacturing Partnership

Oxford Lane Capital Stock

Oxford Lane Capital Navigates Major Overhaul Amid Market Pressure

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com